Hal Barron, Altos Labs
Prior to joining GSK, Dr. Barron was President, at Calico LLC (California Life Company), an Alphabet-funded company that uses advanced technologies to increase understanding of lifespan biology. Prior to this role, he was Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, Dr. Barron was Senior Vice President of Development and Chief Medical Officer. He was a non-executive director and chair of the Science & Technology Committee at Juno Therapeutics, Inc until March 2018, when it was acquired by Celgene Corporation. He also previously served as a non-executive Board director of GRAIL, Inc until it was acquired by Illumina. He was also an Advisory Board Member of Verily Life Sciences LLC until 2021. Dr. Barron holds a BS in Physics from Washington University in St. Louis and a MD from Yale University. He completed his training in Internal Medicine and Cardiology at the University of California, San Francisco. Dr. Barron has been issued several patents for his work in thrombosis and angiogenesis and has published more than 90 papers in peer-reviewed scientific journals. He also continues to teach as an Adjunct Professor of Epidemiology and Biostatistics at the University of California, San Francisco.